Mammarella A, Paoletti V, Barlattani M, Leone G, Filippello C P, Mariani A R
Clin Ter. 1989 Apr 30;129(2):129-34.
Forty patients, mean age 56.87 yrs. with light or moderate essential arterial hypertension were randomized double-blind into two subgroups of 20 subjects each, and submitted to daily combined drug treatment with either captopril 50 mg + hydrochlorothiazide 25 mg (group A) or amiloride 5 mg + hydrochlorothiazide 50 mg (group B). Patients were monitored after the washout period and after 4 and 8 weeks of treatment approximately 20-24 after the last dose. The following parameters were studied: blood pressure, heart rate, body weight, untoward side effects. Standard laboratory tests were performed in all patients after washout and at the end of the 8-week treatment period. Both combinations significantly reduced pressure values but the captopril-hydrochlorothiazide combination reduced blood pressure more readily and proved more effective in reducing diastolic values. There were no dropouts due to subjective side effects which were of little relevance and were equally distributed among the two groups. As for laboratory data, patients taking the captopril-hydrochlorothiazide combination had a statistically significant increase in blood glucose. Neither combination induced significant changes in the other parameters, especially as far as potassemia was concerned.
40例平均年龄为56.87岁的轻度或中度原发性动脉高血压患者被随机双盲分为两个亚组，每组20例，并分别接受每日联合药物治疗，A组为卡托普利50毫克+氢氯噻嗪25毫克，B组为阿米洛利5毫克+氢氯噻嗪50毫克。在洗脱期后以及治疗4周和8周后（最后一剂后约20 - 24小时）对患者进行监测。研究了以下参数：血压、心率、体重、不良反应。在所有患者的洗脱期后以及8周治疗期结束时进行标准实验室检查。两种联合用药均显著降低了血压值，但卡托普利-氢氯噻嗪联合用药更易降低血压，且在降低舒张压值方面更有效。没有因主观不良反应而退出研究的情况，这些不良反应相关性较小且在两组中分布均匀。至于实验室数据，服用卡托普利-氢氯噻嗪联合用药的患者血糖有统计学意义的升高。两种联合用药均未引起其他参数的显著变化，尤其是在血钾方面。
